Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
O95319
UPID:
CELF2_HUMAN
Alternative names:
Bruno-like protein 3; CUG triplet repeat RNA-binding protein 2; CUG-BP- and ETR-3-like factor 2; ELAV-type RNA-binding protein 3; Neuroblastoma apoptosis-related RNA-binding protein; RNA-binding protein BRUNOL-3
Alternative UPACC:
O95319; B7ZAN9; Q7KYU4; Q8N499; Q92950; Q96NW9; Q96RQ5; Q96RQ6; Q9UL67
Background:
CUGBP Elav-like family member 2, known by alternative names such as Bruno-like protein 3 and Neuroblastoma apoptosis-related RNA-binding protein, plays a pivotal role in post-transcriptional gene regulation. It is involved in mRNA splicing, stability, and translation, affecting various cellular processes including muscle development and apoptosis.
Therapeutic significance:
Linked to Developmental and epileptic encephalopathy 97, a condition characterized by severe seizures and cognitive impairment, understanding the role of CUGBP Elav-like family member 2 could open doors to potential therapeutic strategies.